In addition, CARs targeting EIIIB modified to secrete anti-CTLA-4 single-domain antibodies showed decreased expression of PD-1 and PDL-1 on the CAR T cells and improved persistence in an immune-competent tumor model [119]. This evidence concerns the gene CTLA4 and neoplasm.